N/A N=6 The Perceptual Experience of Argus II Users
Retinitis Pigmentosa
Primary: Number of Phosphenes Perceived — 1.09; 1.43; 1.46; 1.41 number of phosphenes — p=0.002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=79 Patient Perception of Visual Distortions
Cataract · Astigmatism
Primary: Visual Distortion Symptoms — 0.89; 0.38; 0.64; 0.38 rating of visual distortion symptoms
N/A N=100 Evaluation of a Night Spectacle Correction Concerning an Improvement of Mesopic Vision Quality
Myopia-Night Blindness
Primary: Night Myopia — -0.30; -0.32 D
N/A N=155 Eye Movements, Visual Perception and Attention
Vision
Primary: Average Performance in Visual Tasks — 74 percentage
Phase 4 N=64 Symfony vs Vivity in Dim Light
Cataract
Primary: Binocular Distance Corrected Intermediate Visual Acuity at 66 cm Under Mesopic Conditions. — 0.27; 0.32 logMAR
N/A N=6 Feasibility Electrical Stimulation Study for Visual Hallucinations
Schizophrenia · Schizoaffective Disorder · Bipolar Disorder
Primary: Steady State Visual Evoked Potential (ssVEP) — 1.725; 1.160; 1.180; 1.005 microvolts — p=0.10
N/A N=20 Visual Outcomes and Patient Satisfaction With Vivity IOL in Post Refractive Patients
Pseudophakia
Primary: Binocular Best Corrected Distance Visual Acuity — -0.05 logMAR
N/A N=21 Visual Activity Evoked by Infrared in Humans After Dark Adaptation
Age Related Macular Degeneration · Retinitis Pigmentosa · Congenital Stationary Night Blindness
Primary: Visual Perception to Infrared: Mean Minimal Intensity (uW) at Which Participants Could See IR Between 900 - 1400 nm. — 0.671770454; 0.809204; 0.205456012; 0.222247 uW…
N/A N=301 Patient Perception of Visual Quality and Function
Cataract
Primary: Use of Corrective Visual Aids (i.e., Spectacles, Contact Lenses) Post Intraocular Lens (IOL) Surgery — 71; 8; 9 participants
N/A N=97 Electric Stimulation of the Eye to Improve Vision After Trauma
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) · Trauma · Multiple Sclerosis (MS)
Primary: Evaluation of the Effectiveness and Safety of Transcorneal Electrical Stimulation to Improve Visual Acuity — -0.23; -0.14; -0.08; -0.06 logMAR
N/A N=56 Single-center, Double-arm, Prospective Clinical Trial to Compare Visual Performance of Non-diffractive Extended Vision and Neutral Aspheric Monofocal Intraocular Lenses
Cataract · Presbyopia
Primary: Binocular Intermediate Vision — -0.02; 0.19 logMAR
Phase 4 N=119 Clinical Investigation of the Vision-R800 Device.
Myopia · Hyperopia · Astigmatism
Primary: Subjective Questionnaire Response — 22; 32; 5; 3 Participants
N/A N=33 Vivity IOL: Emmetropia Compared to Monovision.
Presbyopia
Primary: Binocular Uncorrected Near (40 cm) Visual Acuity — 0.21; 0.39 logMAR
N/A N=110 Maximizing Visual Outcomes With Eyhance IOLs
Pseudophakia
Primary: Comparison of Two Groups Categorized by "Distance With Minimal Intermediate" and "Distance With Enhanced Intermediate/Near" Based on Mean Photopic Binocular BCDVA of…
N/A N=23 Evaluation of Vision Effects of a Cosmetic Tinted Hydrogel Contact Lens
Refractive Error
Primary: The Binocular Functional Visual Performance Under Distance Day Time Conditions (250 cd/m2) for Centrally Presented High Contrasts (HC) Time Controlled Visual Acuity…
N/A N=100 Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues
Parkinson's Disease
Primary: Visual Sampling Parameter: Saccade Frequency During Gait — 0.48; 0.76; 0.67; 0.77 Saccade frequency (sacc/sec)
N/A N=20 A Novel Method for Capturing the Visual Evoked Potential During Spine Surgery Under Total Intravenous Anesthesia
Evoked Potentials, Visual
Primary: Number of Participants With Presence of VEPs — 18 Participants
N/A N=448 Third Eye Retroscope Randomized Clinical Evaluation
Colorectal Neoplasms
Primary: Detection Rates for Adenomas and for Total Polyps — 160; 163; 78; 31 Polyps or adenomas detected
N/A N=230 Visual Outcomes and Patient Satisfaction With Bilateral PanOptix Verses Bilateral Synergy
Pseudophakia
Primary: Binocular DCNVA (Distance Corrected Near Visual Acuity) at 40cm — 0.03; 0.01 logMAR
Phase 2 N=146 A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Change in Humphrey Visual Fields - Total Sensitivity — 1.4; 16.8; -164.8; -66.7 dB
N/A N=26 Environmental Localization Mapping and Guidance for Visual Prosthesis Users
Retinitis Pigmentosa · Visual Impairment · Visual Prosthesis
Primary: Duration of Time to Complete Navigational Tasks as Assessed by the Mean Duration of Travel in Seconds Normalized by the Nominal Path Distance in Meters — 14.54; 14.09…
N/A N=9 Object Finder for a Retinal Prosthesis
Retinitis Pigmentosa
Primary: Performance (Completion Time) Locating a Cell Phone and a Person — 47; 11; 30; 23 time (s)
N/A N=310 Intermediate Vision in Patients With Clareon IOLs Compared to Eyhance IOLs
Pseudophakia
Primary: Non-inferiority of Target-corrected Binocular Intermediate (66 cm) Visual Acuity With Offset — 0.20; 0.19 LogMAR — p=<0.05
N/A N=328 Impact of Experience on Results With the Third Eye Retroscope
Colorectal Neoplasms
Primary: Detection Rates for Adenomas — 100; 16 Adenomas
Phase 2 N=24 Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances
Decrease in Night Vision · Disturbance; Vision, Loss
Primary: Contrast Sensitivity — 0.6; 0.8; 0.9; 0.7 Patches
N/A N=22 Optical Head-Mounted Display Technology for Low Vision Rehabilitation
Retinal Dystrophies · Healthy
Primary: Change in the Planimetric Area of Goldmann Visual Field With the Use of Head-mounted Display Technology Compared to Baseline (Measured in Degrees Squared) — 563.08…
N/A N=193 Clinical Investigation of the AcrySof IQ Vivity Extended Vision Intraocular Lens (IOL)
Aphakia
Primary: Percentage of Subjects Not Bothered at All by Halos (QUVID Question 2.3) — 88.7; 58.1; 58.6 percentage of subjects
N/A N=79 Clinical Evaluation of the Next Generation Phaco System
Cataract
Primary: Proportion of Eyes With Surgeon Satisfaction Rating Score of 4 or 5 — 0.991; 0.991; 0.991; 1.00 Proportion of Eyes
Phase 3 N=144 Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
Dim Light Vision Disturbances
Primary: Percent of Subjects With 3 Lines mLCVA Improvement in Study Eye — 9; 2 Participants
N/A N=13 Understanding Visual Confusion Using Stereoscopic Displays
Diplopia · Binocular Vision Suppression · Binocular; Fusion, With Defective Stereopsis
Primary: Percentage of Total Viewing Time That Peripheral Target is Perceived — 73.56; 59.64; 87.81 Percentage of Time — p=<0.01